论文部分内容阅读
本研究证明,胎儿肝脾细胞经重组IL-2作用96小时,可产生显著的LAK样活性,在重组IL-2 1000u/ml,E:T为100:1其杀伤率分别达60%和62%。如果这一体外试验结果在体内应用中得到证实,无疑将给临床获取LAK细胞提供一条新的途径。
This study demonstrated that the recombinant human hepatocyte and hepatocyte spleen cells could produce significant LAK-like activity after 96 hours of recombinant IL-2. The killing rates of recombinant IL-2 1000u / ml and E: T 100: 1 were 60% and 62% %. If this in vitro test results are confirmed in vivo applications, will undoubtedly provide a new way for clinical access to LAK cells.